Systemic Markers of Lung Function and FEV 1 Decline across Diverse Cohorts.
Debby NgoKatherine A PratteClaudia FlexederHans PetersenHong DangYanlin MaMichelle J KeyesYan GaoShuliang DengBennet D PetersonLaurie A FarrellVictoria M BhambhaniCesar PalaciosJuweria QuadirLucas GillenwaterHanfei XuClaire EmsonChristian GiegerKarsten SuhreJohannes GraumannDeepti JainMatthew P ConomosRussell P TracyXiuqing GuoYongmei LiuW Craig JohnsonElaine CornellPeter DurdaKent D TaylorGeorge J PapanicolaouStephen S RichJerome I RotterStephen I RennardJeffrey L CurtisPrescott WoodruffAlejandro P ComellasEdwin K SilvermanJames D CrapoMartin G LarsonRamachandran S VasanThomas J WangAdolfo CorreaMario SimsJames G WilsonRobert E GersztenGeorge T O'ConnorR Graham BarrDavid CouperJosée DupuisAni ManichaikulWanda O'NealYohannes TesfaigziHolger SchulzRussell P BowlerPublished in: Annals of the American Thoracic Society (2023)
In this study, we identify and validate novel biomarkers and pathways associated with lung function traits in a racially diverse population. Additionally, we identify novel protein markers associated with FEV1 decline. Several protein findings are supported by previously reported genetic signals, highlighting the plausibility of certain biologic pathways. These novel proteins might represent markers for endophenotyping and risk stratification, as well novel molecular targets for treatment of COPD.